Zura Bio Ltd (ZURA) Stock Price, Quote & News

Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that ne...

Industry: Biotechnology

Sector: Healthcare

Phone: 702 825 9872

Website: zurabio.com

Address:

1489 W. Warm Springs Road, Suite 110, Henderson, United States

briefingcom Feb. 25 at 12:55 PM

$ZURA: Zura Bio Limited (-4.3%) announces proposed public offering of Class A Ordinary Shares

1 · Reply

StockNews_Live Feb. 25 at 11:32 AM

$ZURA Zura Bio Limited announced the pricing of its underwritten public offering of 18,200,000 Class A ordinary shares at a price to the public of $6.25 per share. The gross proceeds to Zura from the offeri…

0 · Reply

JeffreyCress Feb. 24 at 9:06 PM

$ZURA offering…

1 · Reply

Quantumup Feb. 24 at 2:55 PM

TD Cowen reiterated $AVTX at a Buy rating and said, Risk/Reward Skewed To Significant Upside For AVTX-009 Phase Il In Large HS Oppy $ABBV $MLTX $ZURA Here's what else TD Cowen had to say in its note to investors: https://x.com/Quantumup1/status/2026309287077658777?s=20

0 · Reply

StockConsultant Feb. 24 at 2:29 PM

$ZURA Zura Bio stock, watch for a bull flag breakout at https://stockconsultant.com/?ZURA

1 · Reply

BillionerOfKing Feb. 23 at 4:49 PM

$ZURA Current Stock Price: $6.54 Contracts to trade: $7.5 ZURA Mar 20 2026 Call Entry: $0.25 Exit: $0.41 ROI: 63% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

BioTuesdays Feb. 23 at 2:42 PM

$ZURA has announced the appointments of Mark Eisner, MD, PhD, and Ajay Nirula, MD, PhD, to its board of directors (BOD), effective February 21, 2026. Neil Graham, MBBS, MD, MPH, stepped down from the BOD on that date. https://biotuesdays.com/2026/02/23/drs-mark-eisner-and-ajay-nirula-join-zura-bios-bod/

0 · Reply

OfficialStocktwitsUser Feb. 21 at 10:47 AM

$ZURA RSI: 59.63, MACD: 0.2412 Vol: 0.23, MA20: 6.14, MA50: 5.34 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

MorrisBuckman207 Feb. 11 at 4:34 PM

$ZURA Zura Bio; biotech (immunology); early-stage; reverse merger vehicle; binary catalysts.

0 · Reply

StockConsultant Feb. 11 at 2:13 PM

$ZURA Zura Bio stock, top of range breakout watch

0 · Reply

Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

Feb 24, 2026, 4:01 PM EST - 1 day ago

Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

Feb 23, 2026, 6:30 AM EST - 3 days ago

Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D.

Feb 4, 2026, 6:30 AM EST - 22 days ago

Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit

Jan 21, 2026, 8:50 AM EST - 5 weeks ago

Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

Jan 12, 2026, 6:30 AM EST - 6 weeks ago

Zura Bio Reports Business Updates and Outlook for 2026

Nov 13, 2025, 6:30 AM EST - 3 months ago

Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates

Aug 20, 2025, 6:30 AM EDT - 6 months ago

Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference

Aug 14, 2025, 8:15 AM EDT - 7 months ago

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

Jul 17, 2025, 4:30 PM EDT - 7 months ago

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2025, 6:30 AM EDT - 8 months ago

Zura Bio Announces Chief Financial Officer Transition

May 27, 2025, 6:30 AM EDT - 9 months ago

Zura Bio to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 6:30 AM EDT - 10 months ago

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 8, 2025, 6:30 AM EDT - 10 months ago

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

Mar 25, 2025, 6:30 AM EDT - 1 year ago

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

Feb 24, 2025, 6:30 AM EST - 1 year ago

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

Dec 23, 2024, 6:30 AM EST - 1 year ago

Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

Nov 25, 2024, 6:30 AM EST - 1 year ago

Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 14, 2024, 4:30 PM EST - 1 year ago

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Nov 7, 2024, 6:30 AM EST - 1 year ago

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Oct 30, 2024, 6:30 AM EDT - 1 year ago

Zura Bio to Participate in Two Upcoming Investor Conferences in November

Sep 3, 2024, 6:00 AM EDT - 1 year ago

CPS HR Consulting Partners with GovInvest to Revolutionize Compensation Consulting with Advanced Technology

OGI

Sep 3, 2024, 6:00 AM EDT - 1 year ago

Zura Bio to Present at Three Upcoming Investor Conferences in September

Aug 13, 2024, 9:21 AM EDT - 1 year ago

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants

Aug 9, 2024, 4:05 PM EDT - 1 year ago

Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants

Jul 12, 2024, 6:10 AM EDT - 1 year ago

Zura Bio Commences Warrant Exchange Offer and Consent Solicitation

Jun 14, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024

Jun 6, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology

Jun 3, 2024, 6:00 AM EDT - 1 year ago

Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024

May 29, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Announces Participation in June Investor Conferences

May 9, 2024, 6:00 AM EDT - 1 year ago

Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 18, 2024, 9:22 AM EDT - 2 years ago

Zura Bio Announces Oversubscribed $112.5 Million Private Placement

Apr 8, 2024, 6:00 AM EDT - 2 years ago

Zura Bio Announces Robert Lisicki as CEO and Director

Mar 28, 2024, 6:00 AM EDT - 2 years ago

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

Mar 4, 2024, 6:00 AM EST - 2 years ago

Zura Bio Announces Participation at March Conferences

Feb 2, 2024, 6:00 AM EST - 2 years ago

Zura Bio Announces Participation at February Investor Conferences

Jan 8, 2024, 6:00 AM EST - 2 years ago

Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO

Jan 3, 2024, 6:00 AM EST - 2 years ago

Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit

Dec 4, 2023, 6:00 AM EST - 2 years ago

Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok

Nov 14, 2023, 6:00 AM EST - 2 years ago

Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors

Nov 13, 2023, 6:30 AM EST - 2 years ago

Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Sep 12, 2023, 5:00 AM EDT - 2 years ago

Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jun 23, 2023, 6:30 AM EDT - 2 years ago

Zura Bio to Join the Russell 2000® and Russell 3000® Indexes

Jun 6, 2023, 4:00 AM EDT - 2 years ago

Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist

Apr 27, 2023, 7:39 AM EDT - 3 years ago

Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases

Apr 14, 2023, 5:00 AM EDT - 3 years ago

Zura Bio Announces Appointment of Chief Scientific Officer

Mar 21, 2023, 6:13 AM EDT - 3 years ago

Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp

Mar 16, 2023, 4:17 PM EDT - 3 years ago

JATT Acquisition Corp Shareholders Approve Proposed Business Combination with Zura Bio Limited

briefingcom Feb. 25 at 12:55 PM

$ZURA: Zura Bio Limited (-4.3%) announces proposed public offering of Class A Ordinary Shares

1 · Reply

StockNews_Live Feb. 25 at 11:32 AM

0 · Reply

JeffreyCress Feb. 24 at 9:06 PM

$ZURA offering…

1 · Reply

Quantumup Feb. 24 at 2:55 PM

0 · Reply

StockConsultant Feb. 24 at 2:29 PM

$ZURA Zura Bio stock, watch for a bull flag breakout at https://stockconsultant.com/?ZURA

1 · Reply

BillionerOfKing Feb. 23 at 4:49 PM

0 · Reply

BioTuesdays Feb. 23 at 2:42 PM

0 · Reply

OfficialStocktwitsUser Feb. 21 at 10:47 AM

0 · Reply

MorrisBuckman207 Feb. 11 at 4:34 PM

$ZURA Zura Bio; biotech (immunology); early-stage; reverse merger vehicle; binary catalysts.

0 · Reply

StockConsultant Feb. 11 at 2:13 PM

$ZURA Zura Bio stock, top of range breakout watch

0 · Reply

notreload_ai Feb. 9 at 2:29 PM

Wedbush gives $ZURA an Outperform rating and $15 target, highlighting upcoming clinical catalysts and potential stock growth through 2026. https://notreload.xyz/wedbush-starts-coverage-on-zura-bio-with-positive-outlook/

0 · Reply

FilingTracker Jan. 27 at 10:23 PM

$ZURA 15.7% position of Athanor Capital revealed in 13D: https://www.sec.gov/Archives/edgar/data/1855644/000110465926007047/xslSCHEDULE_13D_X01/primary_doc.xml

0 · Reply

SMART4TRADER Jan. 22 at 6:45 PM

January 22, 2026 For potential momentum retention $NUAI $ZURA $IAUX

0 · Reply

hitmongreen Jan. 22 at 2:44 PM

$ZURA 🤔

0 · Reply

Shuqishuqi Jan. 22 at 11:31 AM

$ZURA man

0 · Reply

SadyK189 Jan. 22 at 4:56 AM

$ZURA Good. close of daily candle. Key support at 5.15 - 5.50. Next key level to test is 7.1 - 7.6. Currently at 6.40

0 · Reply

Smoothopera1or Jan. 22 at 2:11 AM

$ZURA 7-10$ possible?

0 · Reply

GSP Jan. 21 at 10:18 PM

Big breakout for $ZURA today. .

0 · Reply

GSP Jan. 21 at 10:13 PM

I cover the following stocks in my nightly video. $SPY $ZURA $MLTX $SLDB $ALT

1 · Reply

Yourboyy Jan. 21 at 9:38 PM

$ZURA brooooo

0 · Reply

L7_Trading Jan. 21 at 9:30 PM

Looks like they are going to Halt-Up YGHJ in to Close... YHGJ is breaking out now.. Are they pumping up ticker YHGJ for 400% today!? Its insane what's going on in this crazy market.. Looks like all eyes are going to YHGJ now.. $ATLN $IMTE $PRHI $ZURA wpc

0 · Reply

RunnerSignals Jan. 21 at 9:29 PM

Market Warriors on the Rise! $ZURA $VIR $NFE $IBRX $AIRS started down but blasted back to close strong!

0 · Reply

Market Cap	435.00M
Revenue (ttm)	0.00
Net Income (ttm)	-45.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	302,763
Avg Vol	720,098
Day's Range	N/A - N/A
Shares Out	65.02M
Stochastic %K	87%
Beta	0.21
Analysts	Strong Sell
Price Target	$15.86